Cancer Center Support Grant

摘要 芝加哥大学医学综合癌症中心（UCCCC）正在提交这份竞争性的 更新申请癌症中心支持补助金43-47年。UCCCC的使命是 阐明癌症的决定因素，开发癌症的治疗方法，并通过研究预防癌症， 临床护理、教育和社区参与。我们的癌症研究项目强调转化 和跨学科研究，我们通过促进多元化和跨学科研究之间的合作来实现这一目标 由杰出的基础、转化、临床和人口研究人员组成的专门团队。166名成员 UCCCC被组织成五个已建立的项目，所有项目都以翻译为重点（分子机制 癌症;免疫学和癌症;临床和实验治疗学;高级成像;和癌症 预防和控制）。临床研究是UCCCC多学科活动的主要重点。的 UCCCC在进行所有阶段的临床试验方面有着广泛的记录，并被授予U10 NCTN 获得NCI的领先学术参与站点（LAPS）奖。此外，UCCCC是 肿瘤临床试验联盟和儿童肿瘤学小组（COG），并参与NRG 肿瘤学研究是LAPS的主要成员。2016年，914名患者接受了治疗， 协议，其中383个累积到制药商发起的试验。自上次审查以来（2013-2016年）， UCCCC贡献了2，121篇同行评审出版物。成员得到4050万美元（DC）的同行支持， 经审查的资金和2 370万美元未经同行审查的资金。 本申请中要求为项目领导人提供资金;领导，规划和评估; 发展基金、行政、临床方案和数据管理;方案审查和 监测系统，社区外展和参与;癌症研究职业提升和 相关活动;和10个共享资源（生物信息学、生物统计学、细胞计数和抗体 技术;基因组学;人体免疫监测和cGMP;人体组织资源中心; 集成显微镜;集成小动物成像研究资源;药理学;和转基因 小鼠/胚胎干细胞设施）。 通过深入的机构审查和多方面的战略规划过程，UCCCC有了新的 和强有力的机构承诺，以及一个稳定和经验丰富的领导团队，并已制定和 实施全面战略计划。未来的发展将集中在三大举措上， 优先考虑并加速实验室、临床和转化以及基于社区的癌症研究： 1)开发新的生物标志物、新的治疗方法和新的干预措施来预防癌症; 2）有效地 将有效的治疗和干预措施纳入医疗实践; 3）评估这些措施的影响 健康成果的新方法，以及解决与我们的集水区有关的癌症问题。托换 这些倡议中的每一个都是用于癌症研究和护理的基于计算的模型。

ABSTRACT The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) is submitting this competitive renewal application for its Cancer Center Support Grant for Years 43-47. The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer through research, clinical care, education, and community engagement. Our cancer research programs emphasize translational and transdisciplinary research, and we pursue this goal by promoting collaboration among a diverse and dedicated team of outstanding basic, translational, clinical, and population researchers. The 166 members of the UCCCC are organized into five established programs, all with a translational focus (Molecular Mechanisms of Cancer; Immunology and Cancer; Clinical and Experimental Therapeutics; Advanced Imaging; and Cancer Prevention and Control). Clinical research is a major focus of multidisciplinary activity at the UCCCC. The UCCCC has an extensive record in conducting all phases of clinical trials, and was awarded a U10 NCTN Lead Academic Participating Site (LAPS) award from the NCI. In addition, the UCCCC is a full member of the Alliance for Clinical Trials in Oncology, and the Children's Oncology Group (COG), and participates in NRG Oncology studies as a LAPS main member. In 2016, 914 individual patients were accrued to therapeutic protocols, with 383 accrued to investigator-initiated trials. In the period since the last review (2013-2016), the UCCCC contributed 2,121 peer-reviewed publications. Members are supported by $40.5 million (DC) in peer- reviewed funding, and $23.7 million in non-peer-reviewed funding. Funds are requested in this application for Program Leaders; Leadership, Planning and Evaluation; Developmental Funds, Administration, Clinical Protocol and Data Management; the Protocol Review and Monitoring System, Community Outreach and Engagement; Cancer Research Career Enhancement and Related Activities; and 10 shared resources (Bioinformatics, Biostatistics; Cytometry and Antibody Technology; Genomics; Human Immunologic Monitoring and cGMP; Human Tissue Resource Center; Integrated Microscopy; Integrated Small Animal Imaging Research Resource; Pharmacology; and Transgenic Mouse/Embryonic Stem Cell Facilities). Through an in-depth institutional review and multi-faceted strategic planning process, the UCCCC has new and strong institutional commitments, and a stable and experienced leadership team, and has developed and implemented a comprehensive strategic plan. Future development will focus on three major initiatives, which prioritize and accelerate laboratory, clinical and translational, and community-based cancer research: 1) developing new biomarkers, novel treatments, and new interventions to prevent cancer; 2) efficiently integrating effective treatments and interventions into medical practice; and 3) assessing the impact of these new approaches on health outcomes, and addressing cancers relevant to our catchment area. Underpinning each of these initiatives is computation-based models for cancer research and care.